earnings
confidence high
sentiment positive
materiality 0.90
Supernus Q2 revenue up 32% to $219.1M; raises FY guidance; announces merger with Indivior
SUPERNUS PHARMACEUTICALS, INC.
- Total revenues $219.1M, +32% YoY; growth products revenue $175.7M, +52% YoY.
- Qelbree net sales $89.2M (+15% YoY); GOCOVRI $37.6M (+2%); ONAPGO $13.5M; ZURZUVAE collab rev $35.4M.
- Company raises full-year 2026 financial guidance.
- Agreed to merge with Indivior in all-stock merger of equals, creating diversified CNS company.
- ONAPGO second supplier regulatory submission on track for Q3 2026, potential FDA approval by mid-2027.